Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study
Articolo
Data di Pubblicazione:
2021
Abstract:
PD-1 blockade via pembrolizumab monotherapy has shown antitumour activity and toxicity in patients with relapsed or refractory classical Hodgkin lymphoma. Here, we present interim analyses from the KEYNOTE-204 study evaluating pembrolizumab versus brentuximab vedotin for relapsed or refractory classical Hodgkin lymphoma.
Tipologia CRIS:
1.1 Articolo in rivista
Elenco autori:
Kuruvilla, John; Ramchandren, Radhakrishnan; Santoro, Armando; Paszkiewicz-Kozik, Ewa; Gasiorowski, Robin; Johnson, Nathalie A; Fogliatto, Laura Maria; Goncalves, Iara; de Oliveira, Jose S R; Buccheri, Valeria; Perini, Guilherme F; Goldschmidt, Neta; Kriachok, Iryna; Dickinson, Michael; Komarnicki, Mieczyslaw; Mcdonald, Andrew; Ozcan, Muhit; Sekiguchi, Naohiro; Zhu, Ying; Nahar, Akash; Marinello, Patricia; Zinzani, Pier Luigi
Link alla scheda completa:
Pubblicato in: